These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 28349119)

  • 1. A multinational study distinguishing Alzheimer's and healthy patients using cerebrospinal fluid tau/Aβ42 cutoff with concordance to amyloid positron emission tomography imaging.
    Mo Y; Stromswold J; Wilson K; Holder D; Sur C; Laterza O; Savage MJ; Struyk A; Scheltens P; Teunissen CE; Burke J; Macaulay SL; Bråthen G; Sando SB; White LR; Weiss C; Cowes A; Bush MM; DeSilva G; Darby DG; Rainey-Smith SR; Surls J; Sagini E; Tanen M; Altman A; Luthman J; Egan MF
    Alzheimers Dement (Amst); 2017; 6():201-209. PubMed ID: 28349119
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Concordance Between Cerebrospinal Fluid Biomarkers with Alzheimer's Disease Pathology Between Three Independent Assay Platforms.
    Doecke JD; Rembach A; Villemagne VL; Varghese S; Rainey-Smith S; Sarros S; Evered LA; Fowler CJ; Pertile KK; Rumble RL; Trounson B; Taddei K; Laws SM; Macaulay SL; Bush AI; Ellis KA; Martins R; Ames D; Silbert B; Vanderstichele H; Masters CL; Darby DG; Li QX; Collins S;
    J Alzheimers Dis; 2018; 61(1):169-183. PubMed ID: 29171991
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Concordance between cerebrospinal fluid biomarkers and [11C]PIB PET in a memory clinic cohort.
    Zwan M; van Harten A; Ossenkoppele R; Bouwman F; Teunissen C; Adriaanse S; Lammertsma A; Scheltens P; van Berckel B; van der Flier W
    J Alzheimers Dis; 2014; 41(3):801-7. PubMed ID: 24705549
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Concordance of CSF measures of Alzheimer's pathology with amyloid PET status in a preclinical cohort: A comparison of Lumipulse and established immunoassays.
    Keshavan A; Wellington H; Chen Z; Khatun A; Chapman M; Hart M; Cash DM; Coath W; Parker TD; Buchanan SM; Keuss SE; Harris MJ; Murray-Smith H; Heslegrave A; Fox NC; Zetterberg H; Schott JM
    Alzheimers Dement (Amst); 2021; 13(1):e12131. PubMed ID: 33598527
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of Cerebrospinal Fluid and [11C]PIB PET Biomarkers for Alzheimer's Disease with Updated Protocols.
    Wang MJ; Yi S; Han JY; Park SY; Jang JW; Chun IK; Giau VV; Bagyinszky E; Lim KT; Kang SM; An SS; Park YH; Youn YC; Kim S
    J Alzheimers Dis; 2016 May; 52(4):1403-13. PubMed ID: 27163824
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Concordance of CSF measures of Alzheimer's pathology with amyloid PET status in a preclinical cohort: A comparison of Lumipulse and established immunoassays.
    Keshavan A; Wellington H; Chen Z; Khatun A; Chapman M; Hart M; Cash DM; Coath W; Parker TD; Buchanan SM; Keuss SE; Harris MJ; Murray-Smith H; Heslegrave A; Fox NC; Zetterberg H; Schott JM
    Alzheimers Dement (Amst); 2020; 12(1):e12097. PubMed ID: 32999915
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reciprocal Predictive Relationships between Amyloid and Tau Biomarkers in Alzheimer's Disease Progression: An Empirical Model.
    Krance SH; Cogo-Moreira H; Rabin JS; Black SE; Swardfager W;
    J Neurosci; 2019 Sep; 39(37):7428-7437. PubMed ID: 31350262
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Concordance Between Different Amyloid Immunoassays and Visual Amyloid Positron Emission Tomographic Assessment.
    Janelidze S; Pannee J; Mikulskis A; Chiao P; Zetterberg H; Blennow K; Hansson O
    JAMA Neurol; 2017 Dec; 74(12):1492-1501. PubMed ID: 29114726
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cerebrospinal fluid biomarkers distinguish postmortem-confirmed Alzheimer's disease from other dementias and healthy controls in the OPTIMA cohort.
    Seeburger JL; Holder DJ; Combrinck M; Joachim C; Laterza O; Tanen M; Dallob A; Chappell D; Snyder K; Flynn M; Simon A; Modur V; Potter WZ; Wilcock G; Savage MJ; Smith AD
    J Alzheimers Dis; 2015; 44(2):525-39. PubMed ID: 25391385
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinic-Based Validation of Cerebrospinal Fluid Biomarkers with Florbetapir PET for Diagnosis of Dementia.
    Álvarez I; Aguilar M; González JM; Ysamat M; Lorenzo-Bosquet C; Alonso A; Tartari JP; Romero S; Diez-Fairen M; Carcel M; Pujalte F; Pastor P
    J Alzheimers Dis; 2018; 61(1):135-143. PubMed ID: 29154286
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alzheimer's Disease Normative Cerebrospinal Fluid Biomarkers Validated in PET Amyloid-β Characterized Subjects from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study.
    Li QX; Villemagne VL; Doecke JD; Rembach A; Sarros S; Varghese S; McGlade A; Laughton KM; Pertile KK; Fowler CJ; Rumble RL; Trounson BO; Taddei K; Rainey-Smith SR; Laws SM; Robertson JS; Evered LA; Silbert B; Ellis KA; Rowe CC; Macaulay SL; Darby D; Martins RN; Ames D; Masters CL; Collins S;
    J Alzheimers Dis; 2015; 48(1):175-87. PubMed ID: 26401938
    [TBL] [Abstract][Full Text] [Related]  

  • 12. P-tau/Aβ42 and Aβ42/40 ratios in CSF are equally predictive of amyloid PET status.
    Campbell MR; Ashrafzadeh-Kian S; Petersen RC; Mielke MM; Syrjanen JA; van Harten AC; Lowe VJ; Jack CR; Bornhorst JA; Algeciras-Schimnich A
    Alzheimers Dement (Amst); 2021; 13(1):e12190. PubMed ID: 34027020
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cerebrospinal Fluid Levels of β-Amyloid 40 and β-Amyloid 42 are Proportionately Decreased in Amyloid Positron-Emission Tomography Negative Idiopathic Normal-Pressure Hydrocephalus Patients.
    Kim HJ; Lim TS; Lee SM; Kim TS; Kim Y; An YS; Youn YC; Park SA; Chang J; Moon SY
    J Clin Neurol; 2019 Jul; 15(3):353-359. PubMed ID: 31286708
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Concordance and Diagnostic Accuracy of [11C]PIB PET and Cerebrospinal Fluid Biomarkers in a Sample of Patients with Mild Cognitive Impairment and Alzheimer's Disease.
    Leuzy A; Carter SF; Chiotis K; Almkvist O; Wall A; Nordberg A
    J Alzheimers Dis; 2015; 45(4):1077-88. PubMed ID: 25649653
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma Protein Biomarkers for the Prediction of CSF Amyloid and Tau and [
    Westwood S; Baird AL; Hye A; Ashton NJ; Nevado-Holgado AJ; Anand SN; Liu B; Newby D; Bazenet C; Kiddle SJ; Ward M; Newton B; Desai K; Tan Hehir C; Zanette M; Galimberti D; Parnetti L; Lleó A; Baker S; Narayan VA; van der Flier WM; Scheltens P; Teunissen CE; Visser PJ; Lovestone S
    Front Aging Neurosci; 2018; 10():409. PubMed ID: 30618716
    [No Abstract]   [Full Text] [Related]  

  • 16. Cerebrospinal Fluid Aβ42/40 Corresponds Better than Aβ42 to Amyloid PET in Alzheimer's Disease.
    Lewczuk P; Matzen A; Blennow K; Parnetti L; Molinuevo JL; Eusebi P; Kornhuber J; Morris JC; Fagan AM
    J Alzheimers Dis; 2017; 55(2):813-822. PubMed ID: 27792012
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cerebrospinal Fluid Levels of Amyloid Beta 1-43 Mirror 1-42 in Relation to Imaging Biomarkers of Alzheimer's Disease.
    Almdahl IS; Lauridsen C; Selnes P; Kalheim LF; Coello C; Gajdzik B; Møller I; Wettergreen M; Grambaite R; Bjørnerud A; Bråthen G; Sando SB; White LR; Fladby T
    Front Aging Neurosci; 2017; 9():9. PubMed ID: 28223932
    [No Abstract]   [Full Text] [Related]  

  • 18. CSF biomarkers and amyloid PET: concordance and diagnostic accuracy in a MCI cohort.
    Spallazzi M; Barocco F; Michelini G; Immovilli P; Taga A; Morelli N; Ruffini L; Caffarra P
    Acta Neurol Belg; 2019 Sep; 119(3):445-452. PubMed ID: 30847669
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease.
    Lautner R; Palmqvist S; Mattsson N; Andreasson U; Wallin A; Pålsson E; Jakobsson J; Herukka SK; Owenius R; Olsson B; Hampel H; Rujescu D; Ewers M; Landén M; Minthon L; Blennow K; Zetterberg H; Hansson O;
    JAMA Psychiatry; 2014 Oct; 71(10):1183-91. PubMed ID: 25162367
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease.
    Palmqvist S; Zetterberg H; Mattsson N; Johansson P; ; Minthon L; Blennow K; Olsson M; Hansson O;
    Neurology; 2015 Oct; 85(14):1240-9. PubMed ID: 26354982
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.